Synapse - Phase Ib/II trial of the Bruton's tyrosine kinase (BTK) inhibitor, ibrutinib, in combination with rituximab and lenalidomide in refractory/recurrent primary (PCNSL) and secondary central nervous system lymphoma (SCNSL)

Phase Ib/II trial of the Bruton's tyrosine kinase (BTK) inhibitor, ibrutinib, in combination with rituximab and lenalidomide in refractory/recurrent primary (PCNSL) and secondary central nervous system lymphoma (SCNSL) Meeting Abstract

Authors:	Grommes, C.; Piotrowski, A.; Pentsova, E.; Gavrilovic, I.; Stone, J. B.; Lin, A.; Wongchai, V.; Madzsar, J. T.; Malani, R.; Nolan, C.; Francis, J.; DeAngelis, L.; Schaff, L.; Mellinghoff, I. K.
Abstract Title:	Phase Ib/II trial of the Bruton's tyrosine kinase (BTK) inhibitor, ibrutinib, in combination with rituximab and lenalidomide in refractory/recurrent primary (PCNSL) and secondary central nervous system lymphoma (SCNSL)
Meeting Title:	64th Annual Meeting of the American Society of Hematology (ASH)
Journal Title:	Blood
Volume:	140
Issue:	Suppl. 1
Meeting Dates:	2022 Dec 10-13
Meeting Location:	New Orleans, LA
ISSN:	0006-4971
Publisher:	American Society of Hematology
Date Published:	2022-11-15
Start Page:	3807
End Page:	3808
Language:	English
ACCESSION:	WOS:000893223203372
DOI:	10.1182/blood-2022-157001
PROVIDER:	wos
Notes:	Meeting Abstract -- Source: Wos